People
Craig Fraser, CEO of Windtree Therapeutics, became a U.S. Marine at age 17, learning to perform and lead under pressure in the field before eventually leading in the C-suite.
The deal was originally inked in 2005, where U.S.-based Chiron Corp. made payments to Genentech, a Roche company.
Tofersen is the furthest along of four ASOs currently in clinical development for ALS and as such, there is quite a bit riding on the results of the VALOR trial which has an estimated completion date of August 31st, 2021.
She takes over the role held by oncology research legend José Baselga, who passed away in March from a neurodegenerative disease.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
EQRX is pushing forward with its goal of developing more affordable novel medications that can sustain healthcare systems.
Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.
CEO Emma Walmsley’s vision includes a projected $46 billion in annual sales from the stand-alone pharma company by 2031 and more than 10% operating profit over the next five years.
Brad Perkins, M.D., newly appointed CMO of Karius, has had his eyes on grand scientific achievements since childhood.
As part of the announcement, TRexBio indicated that Johnston Erwin had been appointed CEO and Ovid Trifan would be the company’s CMO.
PRESS RELEASES